Vitamin K2 MK-7 Explained: Forms, Doses and Warfarin Risks

Vitamin K2 MK-7 is the ingredient that turned “vitamin K” from a clotting footnote into a supplement category. The pitch usually attached to it — that it directs calcium into bones and away from arteries — is built on a real mechanism and thinner trials than the adverts suggest. This page separates the three things worth knowing: how MK-7 differs from MK-4, what doses the studies actually used, and the one interaction that is not negotiable.

MK-7 almost always arrives paired with D3; the combined routine is covered in vitamin D3 with K2. For D3 dosing itself, see vitamin D dosage.

What is vitamin K2, exactly?

Vitamin K is a family, not a single compound. Vitamin K1 (phylloquinone) comes from plants, especially leafy greens, and makes up most of the vitamin K in a typical Western diet. Vitamin K2 is the menaquinone group — MK-4, MK-7, MK-8, MK-9 and others — named for the length of their side chains. K2 comes from bacterial fermentation (in foods and, to a debated extent, in your gut) and from animal foods.

All forms share one core job: they are cofactors for the enzyme that carboxylates specific proteins, switching them on. Those proteins include the clotting factors made in the liver, osteocalcin in bone, and matrix Gla protein (MGP) in vessel walls and cartilage. That shared mechanism is why vitamin K status plausibly touches clotting, bone and vascular calcification at once — and why claims should stay modest: activating a protein in a test tube is not the same as preventing a fracture or a heart attack, and the trial record differs sharply by outcome.

MK-7 vs MK-4 — how do they actually differ?

Feature	MK-7	MK-4
Main sources	Natto, bacterial fermentation; supplements	Meat, eggs, dairy; made in tissues from K1
Approximate half-life	~72 hours	~1–2 hours
Typical supplement dose	90–200 mcg once daily	100–1,000 mcg (often token amounts)
Dose used in major studies	180 mcg/day (3-year bone trial)	45 mg/day in 3 divided doses (Japanese drug use)
Practical verdict	Suits once-daily supplements	Hard to sustain levels at supplement doses

The half-life gap is the whole story. Pharmacokinetic work by Schurgers and colleagues, summarised in the Council for Responsible Nutrition’s 2025 safety review, puts MK-7’s half-life at approximately 72 hours and MK-4’s at approximately one hour. A nutrient that lingers for three days accumulates to steady levels on small daily doses. A nutrient gone in an hour does not — which is why MK-4’s credible human data come from 45 mg a day, split into three 15 mg doses, used as a licensed osteoporosis treatment in Japan at doses roughly 200 times what a typical combination capsule contains.

That does not make MK-4 useless. It is the form your tissues make from K1, and it may have roles MK-7 does not. But when a D3+K2 label lists 100 mcg of MK-4 as its headline K2, you are looking at a label decoration, not a studied dose. Our vitamin D3 with K2 hub applies that same test to combined products.

What does the evidence support, honestly?

Bone. The strongest MK-7 trial is a three-year randomised, double-blind study (Knapen and colleagues, Osteoporosis International, 2013): 180 mcg of MK-7 a day in healthy postmenopausal women improved vitamin K status and was associated with less age-related loss of bone mineral density at the lumbar spine and femoral neck, plus improved bone strength estimates. Fracture reduction — the outcome that matters most — was not demonstrated for MK-7 in that trial. MK-4 at 45 mg/day has Japanese trial data including fracture outcomes, at drug doses.

Vascular calcification. The mechanism is coherent (MGP needs vitamin K to inhibit calcification) and the observational data are encouraging — in the Rotterdam Study, higher dietary menaquinone intake tracked with less aortic calcification and lower coronary mortality, while K1 did not. Randomised trials of K2 supplements on calcification progression are smaller and mixed. “Supports cardiovascular health” is the ceiling of honest US wording, and even that should be read as structure/function language, not a promise.

Safety data. The CRN’s 2025 review of more than 40 human trials of MK-7 at 58–463 mcg a day for up to two years found no serious adverse effects attributed to MK-7 and no clinically meaningful effect on coagulation measures in people not taking vitamin K antagonists. It identified 375 mcg a day as the highest observed intake level for healthy adults. Useful context — from an industry-funded body, so treat it as a safety summary, not gospel.

How much vitamin K do you need from all sources?

The NIH adequate intake (AI) for total vitamin K is 120 mcg a day for adult men and 90 mcg a day for adult women, including pregnancy. EFSA set an AI of 70 mcg a day for adults. Neither body set a separate value for K2 or MK-7 — the evidence base was not sufficient — and neither set an upper limit, because vitamin K has shown no toxicity in healthy people at studied intakes.

Two practical conclusions follow. First, a 90–200 mcg MK-7 capsule puts most people at or above total-K reference intakes before food is counted, which is a reasonable place to be. Second, anyone selling you 500 mcg or 1,000 mcg of MK-7 as “optimal” is inventing a target no authority has set and no major trial has used.

Take MK-7 with a meal containing fat — it is fat-soluble, like the D3 it usually travels with. Timing details sit in when to take vitamin D, and blood D levels (there is no routine clinical K2 test) are explained in vitamin D blood levels.

K1 or K2 — do you need both?

Most people already get K1. Leafy green vegetables are rich in phylloquinone, and the NIH adequate intake for total vitamin K was set with typical mixed diets in mind. K1 is handled preferentially by the liver, where the clotting factors are made, which is why K1 deficiency shows up as a clotting problem first. The argument for K2 supplements is about the extrahepatic tissues — bone and blood-vessel walls — where the longer-circulating menaquinones, especially MK-7, reach in greater proportion. That distribution difference is pharmacology, not marketing: it follows directly from the half-life gap in the comparison table above.

The honest limits of that argument deserve equal space. There is no clinical test in routine use that tells you your “K2 status” the way 25(OH)D describes vitamin D status, so K2 supplementation cannot be test-guided the way D3 can. Trials of MK-7 show improved vitamin K status markers (such as reduced undercarboxylated osteocalcin) and modest bone-density benefits in postmenopausal women; they do not yet show the fracture or cardiovascular event reductions that would settle the question. If you eat natto or plenty of aged cheese and leafy greens, your marginal gain from a capsule is plausibly small. If your diet is low in both greens and fermented foods and you already take D3 for bone reasons, 90–180 mcg of MK-7 is a defensible, low-risk addition — priced accordingly, which is to say cheaply.

Who should not take this?

If you take warfarin, acenocoumarol or phenprocoumon, this section is the page. Vitamin K antagonists work by blocking vitamin K recycling. Adding K2 — MK-7, MK-4, or the K1 in a multivitamin — works directly against the drug, can drop your INR, and can raise the risk of the clot the drug was prescribed to prevent. The NIH fact sheet’s guidance for people on warfarin is to keep vitamin K intake about the same amount each day. A supplement is the opposite of that. Do not start, stop or “try” K2 without your anticoagulation clinic. (Direct oral anticoagulants such as apixaban and rivaroxaban do not use the vitamin K pathway, but disclose all supplements to your prescriber anyway.)

Also check with a doctor or pharmacist first if you:

• Are pregnant or breastfeeding. K2 supplement trials in pregnancy are lacking; vitamin K needs are covered by the standard AI through diet and prenatals.
• Have a newborn or young child. Vitamin K for infants is a specific medical protocol (the vitamin K injection or oral drops at birth) — adult K2 products have no place here.
• Take antibiotics long-term, which can reduce gut bacteria that produce menaquinones and lower vitamin K status — a reason to discuss status, not to self-dose.
• Have liver disease or a malabsorption condition (coeliac disease, cystic fibrosis, bile duct problems): fat-soluble vitamin handling is altered and management is clinical.
• Are scheduled for surgery or dental extraction and take anything affecting clotting: disclose K2 use to the team, as you would any supplement.

The bottom line a pharmacist would give you: MK-7 is a low-toxicity, slow-clearing nutrient with one absolute caution — anticoagulants. Respect that line, use the studied 90–200 mcg range, take it with food, and it is one of the simpler supplements to get right.